The main focus in Teva’s innovative portfolio continues to be neuroscience and immunology, with clinical trials for three key ...

Humira is forecast to fall to sixth place by ... "Johnson & Johnson and Mitsubishi Tanabe Pharma’s Stelara (ustekinumab) and Eli Lilly and Sumitomo Dainippon Pharma’s Trulicity (dulaglutide ...

After recent launches of biosimilar versions of Eylea and Stelara, Amgen projects its biosimilar sales will reach $4 billion ...

SAN FRANCISCO -- The pediatric Crohn's disease exclusion diet was associated with clinical remission for children with good ...

Humira's origins lie in the phage display technology ... can claim another two of the six biologic approvals, one of which, Stelara (ustekinumab), is a first-in-class drug. It inhibits the pro ...

The market has been no less demanding for pharma giants as 2025 begins, but last year’s strategies are paying off.

SAN FRANCISCO -- More adults with moderate-to-severe Crohn's disease (CD) reached clinical remission after 6 months on ...

Deals, pipeline updates and geopolitical issues drove the conversation at the 2025 JP Morgan Healthcare conference.

CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...

Humira’s success is down to its incredible ... showing it outperformed Janssen's Stelara. Cosentyx has been one the most successful launches of the last few years, and is set to be a dominant ...